Australia · Delayed Price · Currency is AUD Argent BioPharma Company Description
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom.
The company’s principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer’s.
It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management.
The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited.
Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
| Country | Australia |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Roby Zomer |
Contact Details
Address: 295 Rokeby Road Subiaco, Washington 6008 Australia | |
| Phone | 61 8 6555 2950 |
| Website | argentbiopharma.com |
Stock Details
| Ticker Symbol | RGT |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000MXC6 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Roby Reuven Zomer | Co-Founder, MD, Chief Executive Officer and Chairman |
| Andrew Chapman B.Bus(Econ), DFP, GradDipAppFin | Executive Director |
| Shachar Shimony | Group General Counsel |
| Amir Polak | Chief Pharmaceutical Development Officer |
| Dr. Nadya Lisovoder | Chief Medical Officer |
| Sasha Friedman | Head of Information Systems |
| Yair Tal | Chief Information Security Officer |
| Sanja Cacovich | Head of Non-Pharmaceutical Operations |